RU2018132042A - Применение ингибиторов активности или функции pi3k для лечения первичного синдрома шегрена - Google Patents
Применение ингибиторов активности или функции pi3k для лечения первичного синдрома шегрена Download PDFInfo
- Publication number
- RU2018132042A RU2018132042A RU2018132042A RU2018132042A RU2018132042A RU 2018132042 A RU2018132042 A RU 2018132042A RU 2018132042 A RU2018132042 A RU 2018132042A RU 2018132042 A RU2018132042 A RU 2018132042A RU 2018132042 A RU2018132042 A RU 2018132042A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- syndrome
- treatment
- primary
- shehren
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Применение 1-{(S)-3-[6-(6-Метокси-5-трифторметил-пиридин-3-ил)-5,6,7,8-тетрагидро-пиридо[4,3-d]пиримидин-4-иламино]-пирролидин-1-ил}-пропан-1-она или его фармацевтически приемлемых солей для лечения первичного синдрома Шегрена.
2. Применения по п.1, где соединение представляет собой фосфатную соль 1-{(S)-3-[6-(6-метокси-5-трифторметил-пиридин-3-ил)-5,6,7,8-тетрагидро-пиридо[4,3-d]пиримидин-4-иламино]пирролидин-1-ил}-пропан-1-она.
3. Применение по п.1 или 2, где стандартная доза составляет 10-100 мг активного ингредиента для субъкта-человека весом примерно 40-200 кг.
4. Применение по п.1 или 2, где стандартная доза составляет 70 мг активного ингредиента для субъкта-человека весом примерно 50-70 кг.
5. Применение по п.3 или 4, где введение осуществляют два раза в день.
6. Фармацевтическая композиция, содержащая терапевтически эффективное количество соединения для применения по п.1 или 2 и один или более фармацевтически приемлемых носителей.
7. Комбинация, содержащая терапевтически эффективное количество соединения для применения по п.1 или 2 и один или более терапевтически активных агентов.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16155123 | 2016-02-10 | ||
| EP16155123.9 | 2016-02-10 | ||
| EP16186188.5 | 2016-08-29 | ||
| EP16186188 | 2016-08-29 | ||
| PCT/IB2017/050743 WO2017118965A1 (en) | 2016-02-10 | 2017-02-10 | Use of inhibitors of the activity or function of pi3k for the treatment of primary sjögren's syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018132042A true RU2018132042A (ru) | 2020-03-10 |
| RU2018132042A3 RU2018132042A3 (ru) | 2020-05-15 |
| RU2749731C2 RU2749731C2 (ru) | 2021-06-16 |
Family
ID=58016749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018132042A RU2749731C2 (ru) | 2016-02-10 | 2017-02-10 | Применение ингибиторов активности или функции pi3k для лечения первичного синдрома шегрена |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190038628A1 (ru) |
| EP (2) | EP3413894B1 (ru) |
| JP (1) | JP7132123B2 (ru) |
| KR (1) | KR20180108651A (ru) |
| CN (1) | CN108601786B (ru) |
| AU (1) | AU2017204936B2 (ru) |
| BR (1) | BR112018015272A2 (ru) |
| CA (1) | CA3011205A1 (ru) |
| CL (1) | CL2018001871A1 (ru) |
| CY (1) | CY1122989T1 (ru) |
| DK (1) | DK3413894T3 (ru) |
| ES (1) | ES2797091T3 (ru) |
| HK (1) | HK1257288A1 (ru) |
| HR (1) | HRP20200916T1 (ru) |
| HU (1) | HUE050632T2 (ru) |
| IL (1) | IL260274A (ru) |
| LT (1) | LT3413894T (ru) |
| MX (1) | MX2018009758A (ru) |
| PH (1) | PH12018501490A1 (ru) |
| PL (1) | PL3413894T3 (ru) |
| PT (1) | PT3413894T (ru) |
| RS (1) | RS60477B1 (ru) |
| RU (1) | RU2749731C2 (ru) |
| SI (1) | SI3413894T1 (ru) |
| WO (1) | WO2017118965A1 (ru) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590057A (en) | 2008-07-17 | 2012-08-31 | Novartis Ag | Compositions and methods of use for therapeutic antibodies that bind a BAFFR polypeptide |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| EP2723740A1 (en) * | 2011-06-27 | 2014-04-30 | Novartis AG | Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives |
| WO2015162584A1 (en) * | 2014-04-24 | 2015-10-29 | Novartis Ag | Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide |
-
2017
- 2017-02-10 EP EP17704548.1A patent/EP3413894B1/en active Active
- 2017-02-10 ES ES17704548T patent/ES2797091T3/es active Active
- 2017-02-10 PL PL17704548T patent/PL3413894T3/pl unknown
- 2017-02-10 BR BR112018015272-2A patent/BR112018015272A2/pt not_active Application Discontinuation
- 2017-02-10 CN CN201780010050.XA patent/CN108601786B/zh active Active
- 2017-02-10 SI SI201730288T patent/SI3413894T1/sl unknown
- 2017-02-10 EP EP20162199.2A patent/EP3695840A1/en not_active Withdrawn
- 2017-02-10 WO PCT/IB2017/050743 patent/WO2017118965A1/en active Application Filing
- 2017-02-10 LT LTEP17704548.1T patent/LT3413894T/lt unknown
- 2017-02-10 AU AU2017204936A patent/AU2017204936B2/en active Active
- 2017-02-10 RU RU2018132042A patent/RU2749731C2/ru active
- 2017-02-10 US US16/075,066 patent/US20190038628A1/en not_active Abandoned
- 2017-02-10 HU HUE17704548A patent/HUE050632T2/hu unknown
- 2017-02-10 MX MX2018009758A patent/MX2018009758A/es active IP Right Grant
- 2017-02-10 DK DK17704548.1T patent/DK3413894T3/da active
- 2017-02-10 RS RS20200668A patent/RS60477B1/sr unknown
- 2017-02-10 PT PT177045481T patent/PT3413894T/pt unknown
- 2017-02-10 KR KR1020187022701A patent/KR20180108651A/ko not_active Application Discontinuation
- 2017-02-10 CA CA3011205A patent/CA3011205A1/en active Pending
- 2017-02-10 JP JP2018542236A patent/JP7132123B2/ja active Active
-
2018
- 2018-06-26 IL IL260274A patent/IL260274A/en unknown
- 2018-07-10 CL CL2018001871A patent/CL2018001871A1/es unknown
- 2018-07-11 PH PH12018501490A patent/PH12018501490A1/en unknown
- 2018-12-21 HK HK18116434.0A patent/HK1257288A1/zh unknown
-
2020
- 2020-06-08 HR HRP20200916TT patent/HRP20200916T1/hr unknown
- 2020-06-10 CY CY20201100526T patent/CY1122989T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108601786A (zh) | 2018-09-28 |
| IL260274A (en) | 2018-07-31 |
| EP3413894A1 (en) | 2018-12-19 |
| CA3011205A1 (en) | 2017-07-13 |
| PL3413894T3 (pl) | 2020-10-05 |
| DK3413894T3 (da) | 2020-06-15 |
| US20190038628A1 (en) | 2019-02-07 |
| EP3413894B1 (en) | 2020-03-11 |
| MX2018009758A (es) | 2018-09-11 |
| SI3413894T1 (sl) | 2020-09-30 |
| JP2019508413A (ja) | 2019-03-28 |
| CY1122989T1 (el) | 2021-10-29 |
| KR20180108651A (ko) | 2018-10-04 |
| HK1257288A1 (zh) | 2019-10-18 |
| HUE050632T2 (hu) | 2020-12-28 |
| BR112018015272A2 (pt) | 2018-12-18 |
| WO2017118965A1 (en) | 2017-07-13 |
| JP7132123B2 (ja) | 2022-09-06 |
| RU2018132042A3 (ru) | 2020-05-15 |
| EP3695840A1 (en) | 2020-08-19 |
| CN108601786B (zh) | 2021-11-02 |
| LT3413894T (lt) | 2020-07-10 |
| AU2017204936A1 (en) | 2018-07-19 |
| PH12018501490A1 (en) | 2019-03-25 |
| AU2017204936B2 (en) | 2019-06-27 |
| PT3413894T (pt) | 2020-06-16 |
| RS60477B1 (sr) | 2020-08-31 |
| RU2749731C2 (ru) | 2021-06-16 |
| HRP20200916T1 (hr) | 2020-09-18 |
| ES2797091T3 (es) | 2020-12-01 |
| CL2018001871A1 (es) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| HRP20210901T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja sekundarne nesanice | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| NZ751418A (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| HRP20161674T1 (hr) | 4-(8-METOKSI-1-((1-METOKSIPROPAN-2-IL)-2-(TETRAHIDRO-2H-PIRAN-4-IL)-1H-IMIDAZO[4,5-c]KINOLIN-7-IL)-3,5-DIMETILIZOKSAZOL I NJEGOVA UPOTREBA KAO INHIBITORA BROMODOMENE | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| MX2019013643A (es) | Terapia de combinacion de 7-bencil-10-(2-metilbencil)-2,6,7,8,9,10 -hexahidroimidazo[1,2-a]pirido [4,3-d]pirimidin-5(3h)-ona. | |
| MX2014010494A (es) | Derivados de pirazolo-triazina como inhibidores selectivos de cinasas dependientes de ciclina. | |
| RU2015102772A (ru) | Бензодиазелипы для мелкоклеточного рака легкого | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| JP2016539156A5 (ru) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| MX2022001966A (es) | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. | |
| MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| EA201270651A1 (ru) | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения | |
| RU2019132893A (ru) | Комбинированная терапия для лечения рака молочной железы | |
| RU2019108259A (ru) | Комбинированная терапия для лечения гепатоцеллюлярной карциномы | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| SI2729474T1 (en) | (TIENO (2,3-b) (1,5) BENZOXAZEPIN-4-YL) PIPERAZINE-1-IL COMPOUNDS AS TWO ACTIVE H1 INVERTIVE AGENTS / 5-HT2A ANTAGONISTS | |
| HRP20200472T1 (hr) | Liječenje alopecije areate |